Written Question · S2W-20685 · Session 2
How many NHS boards have made bortezomib (Velcade) available to patients who have requested such treatment.
The question
To ask the Scottish Executive how many NHS boards have made bortezomib (Velcade) available to patients who have requested such treatment.
The answer
Information on drug treatments given in hospitals is not available centrally. Data collected centrally relate to prescribed items dispensed by community pharmacists and dispensing doctors. These data are not patient-specific.
The Scottish Medicines Consortium has recommended that bortezomib is accepted for use within NHS Scotland for the treatment of patients with multiple myeloma who have already received at least two therapies, have seen their disease progress on the last therapy and who are unresponsive to alternative licensed treatments for this stage of the disease.
NHS boards should therefore ensure that bortezomib is made available according to clinical need.
The Scottish Medicines Consortium has recommended that bortezomib is accepted for use within NHS Scotland for the treatment of patients with multiple myeloma who have already received at least two therapies, have seen their disease progress on the last therapy and who are unresponsive to alternative licensed treatments for this stage of the disease.
NHS boards should therefore ensure that bortezomib is made available according to clinical need.
In the Official Report
No contribution in the Official Report cites S2W-20685 by reference.